Zobrazeno 1 - 10
of 67
pro vyhledávání: ''
Autor:
Ali Al-Zahrani, Taher Al-Tweigeri, Osama Al Malik, Asma Tulbah, Adher Al-Sayed, Said Dermime, Mohamed Alshabanah, Adnan Ezzat, Naser Elkum, Dahish Ajarim
Publikováno v:
BASE-Bielefeld Academic Search Engine
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 222 (2007)
Background Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female breast cancers comparing to 6.5
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Publikováno v:
BMC cancer, 16:712. BioMed Central Ltd.
BMC Cancer
BMC Cancer
Background: Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer. We
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower ca
Publikováno v:
BMC Cancer
Background This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the maintenance of relative dose in
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Publikováno v:
BMC Cancer
Background Dermatomyositis is an autoimmune myopathy characterized by proximal muscle weakness, muscle inflammation, and typical skin findings. It is a rare disease with an incidence of ~1/100 000. About 15–30 % of adult-onset cases are caused by u
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 260 (2011)
BMC Cancer, Vol 11, Iss 1, p 260 (2011)
Background Our objective was to measure myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) risk associated with radiation and/or chemotherapy breast cancer (BC) treatment. Methods Our study cohort was composed of BC patients diagnose
Autor:
Barbara Perić, Radan Dzodic, Rok Petric, Gasper Pilko, Hana Besic, Jan Zmuc, Nikola Besic, Andraz Perhavec
Publikováno v:
BMC Cancer
Background The population of elderly people is increasing and so is the population of breast cancer patients aged ≥80 years. The aim of our retrospective study was to identify independent prognostic factors for the duration of breast cancer-specifi